🫁

Respiratory

109 drugs in pipeline from 10 companies

109

Drugs in Pipeline

Companies

Upcoming Catalysts

109

Phase 3 Trials

Upcoming Catalysts

Tomorrow

LUNGEarnings$54M

LUNG Earnings Report

Jul 29Confirmed

Source

Jul '26

MRNAPhase 3$25.4B

mRNA-1345 Phase 3 Est. Readout

mRNA-1345• Respiratory Syncytial Virus1,153

Jul 2026~Confirmed

CT.gov

00%

days

ZLABPDUFA$1.6B

Phase 3?Unknown

FDA PDUFA Date Elzovantinib (priority)

Investigator's Choice of Therapy• Small-cell Lung Cancer

Jul 31Confirmed

SEC

Jul '26

MRKPhase 3$281.2B

✗Negative

Pembrolizumab Phase 3 Est. Readout

pembrolizumab• Non-small Cell Lung Cancer1,397

Jul 2026~Confirmed

CT.gov

View all catalysts

Pipeline by Phase

Phase 3

109

Active Companies

AZNCF

ASTRAZENECA PLC

20 drugs

GILD

Gilead Sciences, Inc.

NOVARTIS AG

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR

2 drugs

CELG-RI

BRISTOL MYERS SQUIBB CO

MERCK

GSK plc

TEVA PHARMACEUTICAL INDUSTRIES LTD

BAYER

AstraZeneca PLC

Related Conditions

respiratorylungpulmonarycopdasthmaipfcystic fibrosisbronchitispneumoniaardsfibrosissleep apnea